ATXS — Astria Therapeutics Share News
0.000.00%
Last trade - 00:00- $718.13m
- $585.73m
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Astria Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Astria Therapeutics Q1 Operating Expenses USD 36.995 Million
Astria Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Astria Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Astria Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Astria Therapeutics posts marginally smaller-than-expected quarterly net loss per share
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Astria Therapeutics Announces FDA Clearance Of IND Application For STAR-0310
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Astria Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: European Commission Grants Orphan Medicinal Product Designation For Navenibart, Astria Therapeutics’ Investigational Therapy For The Treatment Of Hereditary Angioedema
U.S. STOCKS ON THE MOVE-FedEx, United Parcel Service, Autodesk
Astria rises on FDA's orphan drug tag for its genetic disorder treatment
Brief: Astria Therapeutics Receives FDA Orphan Drug Designation For Navenibart (Star-0215)